The U.S. Centers for Disease Control and Prevention advised against using AstraZeneca Plc’s FluMist nasal vaccine in the upcoming flu season after a panel found it wasn’t effective enough in the last three influenza seasons.
The CDC’s findings contrasts with AstraZeneca’s own studies about the efficacy of the inhaled product, which garnered sales of $206 million in the U.S. in the last fiscal year, the London-based drugmaker said in a statement.
The CDC advice means U.S. demand for the vaccine will probably be “very limited” in the second half, so AstraZeneca will take an inventory writedown of about $80 million in the second quarter. The guidance for the full year remains unchanged, the company said.
“AstraZeneca is working with the CDC to better understand its data to help ensure eligible patients continue to receive the vaccine in future seasons in the U.S.,” it said.
The distribution and use of the vaccine in other countries is “progressing as planned for the forthcoming influenza season,” the company said.